Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "ProSolv CardioVascular" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about ProSolv CardioVascular for you to read. Along with our medical data and news we also list ProSolv CardioVascular Clinical Trials, which are updated daily. BioPortfolio also has a large database of ProSolv CardioVascular Companies for you to search.
The first-of-its-kind continuing medical education-certified conference will feature 25 world-renowned experts across multiple therapeutic areas Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), will host the first annual International Congress on the Future of Neurology™ conferenc...
Thank you to everyone who joined us at #ACC19! We look forward to advancing our research with the aim of improving care for patients living with cardiovascular, renal and metabolic diseases.pic.twitter.com/SwqL7wYbcA
Thank you to everyone who joined us at #ACC19! We look forward to advancing our research with the aim of improving care for patients living with cardiovascular, renal and metabolic diseases. pic.twitter.com/SwqL7wYbcA
Rex Medical, L.P., a medical device design and development company, today announced the successful completion of enrollment in the Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization (REVEAL) IDE clinical trial. The REVEAL trial is a single arm, prospective study to evaluate the safety and effectiven...
According to Coherent Market Insights, the global specialty injectable generics market was valued at US$ 31,300 million in 2017, and is projected to exhibit a CAGR of 10.4% over the forecast period (2018 – 2026). Key Trends and Analysis of the Specialty Injectable Generics Market: Increasing prevalence of chronic diseases such as cancer...
Diassess Inc., a developer of rapid, accurate, point-of-care infectious disease tests, announced today that Mr. Engelson has joined as President & Chief Executive Officer effective February 8, 2019. Mr. Engelson brings three decades of medical device innovation and commercialization experience. Mr. Engelson previously served as Chief Executive Officer at ...
Mentice AB, the world-leading provider of endovascular performance solutions, has signed an agreement with the nonprofit public service RAD-AID to donate high-fidelity simulators for Interventional Radiology (IR) procedure training in various resource-constrained regions of the world. Under the agreement, Mentice pledges to contribute simulator softwa...
With regulatory approval in Europe of its innovative NEXUS™ Stent Graft System, Endospan intends to transform the treatment of life-threatening Aortic Arch Disease from a high-risk open surgery into a minimally invasive aortic arch repair for both aneurysms and dissections. Endospan, a pioneer in off-the-shelf, minimally invasive endovascular repair ...
How common are undetermined cause of deaths in cardiovascular outcomes trials, and what are the implications of these findings? Circulation
What do we know about the efficacy and safety of conventional cardioversion methods in obese patients? Should alternative techniques be considered in this population? Journal of Cardiovascular Electrophysiology
AZ's Farxiga reduces major adverse cardiovascular event risk in type 2 #diabetes, new data shows http://bit.ly/2Hvk7o2 #pharma @AstraZeneca pic.twitter.com/6b1TUnxMc6
AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing the drug’s efficacy in reducing the relative risk of major adverse cardiovascular events (MACE) in patients with type-2 diabetes (T2D) who had a prior heart attack. Findings from a pre-specified sub-analysis indicated that the therapy reduced the r...
World’s-First Ultra-High Resolution CT System Delivers Twice the Resolution of Today’s CT Systems Johns Hopkins Medicine now has access to the first Ultra-High Resolution CT (UHR CT) for research capabilities, delivering twice the resolution of today’s CT systems, thanks to the installation of the Aquilion Precision™ from
The prospective trial, which used objectively measured movement, found that the performance of regular household tasks was associated with significant reductions in cardiovascular risk. Medscape Medical News
The so-called Framingham cardiovascular risk calculator was developed in 1991 on the basis of data gathered in the USA between 1968 and 1975. It is named after the town of the same name in Massachusetts, where a systematic evaluation of heart health had previously been conducted in the late 1940s.
Taking a high dose of icosapent ethyl--a pure and stable prescription form of the omega-3 fatty acid known as EPA--significantly reduces the occurrence of first, subsequent and total ischemic events, including heart attacks, strokes and related deaths, among people at high cardiovascular risk despite already being on statin therapy, according to research presented at the American College of Cardio...
Aging immigrants' risk for cardiovascular disease may be heightened by their lack of health insurance, particularly among those who recently arrived in the United States, finds a study led by researchers at NYU Rory Meyers College of Nursing.
BEDMINSTER, N.J., and DUBLIN, Ireland, March 19, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, in addition to its previously announced data from scientific presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session from March 16-18, 2019 in New Orleans, LA, announced data from...
(New York University) Aging immigrants' risk for cardiovascular disease may be heightened by their lack of health insurance, particularly among those who recently arrived in the United States, finds a study led by researchers at NYU Rory Meyers College of Nursing. The findings are published in the Journal of Nursing Scholarship.
Aspirin should be used very selectively in the primary prevention of artherosclerotic cardiovascular disease, according to new guidelines from the...
New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.
To address cardiovascular, renal and metabolic diseases, we strive to deliver transformative science that aims to improve treatment practices and health for millions of patients worldwide. Find out more about our approach: http://bit.ly/2TyqAVK #ACC19p
To address cardiovascular, renal and metabolic diseases, we strive to deliver transformative science that aims to improve treatment practices and health for millions of patients worldwide. Find out more about our approach: http://bit.ly/2TyqAVK #ACC19 pic.twitter.com/n0dPBOzVvc
MONDAY, March 18, 2019 -- Few patients are optimally adherent to statins, although adherence is associated with a reduced risk for major adverse cardiovascular events (MACE), according to a study presented at the annual meeting of the American...
Joint program between Children’s Hospital of Philadelphia and Penn Medicine is the first Delaware Valley institution to have earned ACHA Adult Congenital Heart Disease (ACHD) Accreditation MEDIA, Pa. (PRWEB) March 18, 2019 In recognition of its expertise in serving adults with congenital heart disease (CHD), the Philadelphia Adult Congenital Heart Center has received accreditation from the Adul...
On the basis of ODYSSEY OUTCOMES results, alirocumab is now approved in Europe to reduce cardiovascular risk in adults with established disease. International Approvals